Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy

Nature Genetics

Volumn 42, Issue 8, 2010, Pages 715-721

  Barretina, Jordi ^a,b   Taylor, Barry S ^c,d   Banerji, Shantanu ^a,b   Ramos, Alexis H ^a,b   Lagos Quintana, Mariana ^c   Decarolis, Penelope L ^c   Shah, Kinjal ^a,b   Socci, Nicholas D ^c   Weir, Barbara A ^a,b   Ho, Alan ^c   Chiang, Derek Y ^a,b   Reva, Boris ^c   Mermel, Craig H ^a,b   Getz, Gad ^b   Antipin, Yevgenyi ^c   Beroukhim, Rameen ^a,b   Major, John E ^c   Hatton, Charles ^a   Nicoletti, Richard ^a   Hanna, Megan ^a   Sharpe, Ted ^b   Fennell, Tim J ^b   Cibulskis, Kristian ^b   Onofrio, Robert C ^b   Saito, Tsuyoshi ^c   Shukla, Neerav ^c   Lau, Christopher ^c   Nelander, Sven ^c   Silver, Serena J ^b   Sougnez, Carrie ^b   Viale, Agnes ^c   Winckler, Wendy ^a,b   Maki, Robert G ^b   Garraway, Levi A ^e   Lash, Alex ^c   Greulich, Heidi ^c   Root, David E ^b   Sellers, William R ^e   Schwartz, Gary K ^c   Antonescu, Cristina R ^c   Lander, Eric S ^b   Varmus, Harold E ^c   Ladanyi, Marc ^c   Sander, Chris ^c   Meyerson, Matthew ^a,b   Singer, Samuel ^c   more..

^a HARVARD MEDICAL SCHOOL   (United States)

^b BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

^e NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE 4; MESSENGER RNA; PROTEIN; PROTEIN KINASE B; PROTEIN NF1; PROTEIN P53; PROTEIN PIK3CA; PROTEIN YEATS4; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; BIOLOGICAL THERAPY; CELL PROLIFERATION; CHILD; COPY NUMBER VARIATION; DNA SEQUENCE; FEMALE; FIBROMYXOSARCOMA; GENE DELETION; GENE EXPRESSION; GENE MUTATION; GENOMICS; HUMAN; LEIOMYOSARCOMA; LIPOSARCOMA; MAJOR CLINICAL STUDY; MALE; MYXOSARCOMA; NUCLEOTIDE SEQUENCE; PLEOMORPHIC LIPOSARCOMA; POINT MUTATION; PRIORITY JOURNAL; ROUND CELL LIPOSARCOMA; SCHOOL CHILD; SOFT TISSUE SARCOMA; SYNOVIAL SARCOMA; TUMOR SUPPRESSOR GENE;

ADULT; AGED; FEMALE; GENES, TUMOR SUPPRESSOR; GENOME; HISTIOCYTOMA, MALIGNANT FIBROUS; HUMANS; LIPOSARCOMA; MALE; MIDDLE AGED; MUTATION; SARCOMA;

EID: 77955090106     PISSN: 10614036     EISSN: 15461718     Source Type: Journal    
DOI: 10.1038/ng.619     Document Type: Article

References (54)

1. Jemal A., et al. Cancer statistics 2009. CA Cancer J. Clin. 59, 225-249 (2009).
2. Fletcher, C., Unni, K. & Mertens, F. (eds.) Pathology and Genetics of Tumors of Soft Tissue and Bone 427 (International Agency for Research on Cancer Press, Lyon, France, 2002).
3. Heinrich, M.C. et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 299, 708-710 (2003).
4. Hirota, S. et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279, 577-580 (1998). (Pubitemid 28067289)
5. Demetri, G.D. et al. Effcacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N. Engl. J. Med. 347, 472-480 (2002).
6. van de Rijn, M. & Fletcher, J.A. Genetics of soft tissue tumors. Annu. Rev. Pathol. 1, 435-466 (2006).
7. Ding, L. et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455, 1069-1075 (2008).
8. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defnes human glioblastoma genes and core pathways. Nature 455, 1061-1068 (2008).
9. Greenman, C. et al. Patterns of somatic mutation in human cancer genomes. Nature 446, 153-158 (2007).
10. Velculescu, V.E. Defning the blueprint of the cancer genome. Carcinogenesis 29, 1087-1091 (2008).
11. King, A.A., Debaun, M.R., Riccardi, V.M. & Gutmann, D.H. Malignant peripheral nerve sheath tumors in neurofbromatosis 1. Am. J. Med. Genet. 93, 388-392 (2000).
12. Maertens, O. et al. Molecular pathogenesis of multiple gastrointestinal stromal tumors in NF1 patients. Hum. Mol. Genet. 15, 1015-1023 (2006).
13. Maertens, O. et al. Comprehensive NF1 screening on cultured Schwann cells from neurofbromas. Hum. Mutat. 27, 1030-1040 (2006).
14. Upadhyaya, M. et al. Characterization of the somatic mutational spectrum of the neurofbromatosis type 1 (NF1) gene in neurofbromatosis patients with benign and malignant tumors. Hum. Mutat. 23, 134-146 (2004).
15. Singer, S. et al. Gene expression profling of liposarcoma identifes distinct biological types/subtypes and potential therapeutic targets in well-differentiated and dedifferentiated liposarcoma. Cancer Res. 67, 6626-6636 (2007).
16. Antonescu, C.R. et al. Prognostic impact of P53 status, TLS-CHOP fusion transcript structure, and histological grade in myxoid liposarcoma: a molecular and clinicopathologic study of 82 cases. Clin. Cancer Res. 7, 3977-3987 (2001).
17. Samuels, Y. et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 304, 554 (2004). (Pubitemid 38541907)
18. Barbareschi, M. et al. Different prognostic roles of mutations in the helical and kinase domains of the PIK3CA gene in breast carcinomas. Clin. Cancer Res. 13, 6064-6069 (2007).
19. Huang, C.H. et al. The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations. Science 318, 1744-1748 (2007).
20. Miled, N. et al. Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit. Science 317, 239-242 (2007).
21. Yuan, T.L. & Cantley, L.C. PI3K pathway alterations in cancer: variations on a theme. Oncogene 27, 5497-5510 (2008).
22. Beroukhim, R. et al. Assessing the signifcance of chromosomal aberrations in cancer: methodology and application to glioma. Proc. Natl. Acad. Sci. USA 104, 20007-20012 (2007).
23. Taylor, B.S. et al. Functional copy-number alterations in cancer. PLoS One 3, e3179 (2008).
24. Idbaih, A. et al. Myxoid malignant fbrous histiocytoma and pleomorphic liposarcoma share very similar genomic imbalances. Lab. Invest. 85, 176-181 (2005).
25. König, R. et al. A probability-based approach for the analysis of large-scale RNAi screens. Nat. Methods 4, 847-849 (2007).
26. Luo, B. et al. Highly parallel identifcation of essential genes in cancer cells. Proc. Natl. Acad. Sci. USA 105, 20380-20385 (2008).
27. Futreal, P.A. et al. A census of human cancer genes. Nat. Rev. Cancer 4, 177-183 (2004).
28. Malumbres, M. & Barbacid, M. Cell cycle, CDKs and cancer: a changing paradigm. Nat. Rev. Cancer 9, 153-166 (2009).
29. Park, J.H. & Roeder, R.G. GAS41 is required for repression of the p53 tumor suppressor pathway during normal cellular proliferation. Mol. Cell. Biol. 26, 4006-4016 (2006).
30. Italiano, A. et al. HMGA2 is the partner of MDM2 in well-differentiated and dedifferentiated liposarcomas whereas CDK4 belongs to a distinct inconsistent amplicon. Int. J. Cancer 122, 2233-2241 (2008).
31. Müller, C.R. et al. Potential for treatment of liposarcomas with the MDM2 antagonist Nutlin-3A. Int. J. Cancer 121, 199-205 (2007).
32. Santarius, T., Shipley, J., Brewer, D., Stratton, M.R. & Cooper, C.S. A census of amplifed and overexpressed human cancer genes. Nat. Rev. Cancer 10, 59-64 (2010).
33. Garcia-Echeverria, C. & Sellers, W.R. Drug discovery approaches targeting the PI3K/Akt pathway in cancer. Oncogene 27, 5511-5526 (2008).
34. Johannessen, C.M. et al. The NF1 tumor suppressor critically regulates TSC2 and mTOR. Proc. Natl. Acad. Sci. USA 102, 8573-8578 (2005).
35. Higgins, M.E., Claremont, M., Major, J.E., Sander, C. & Lash, A.E. CancerGenes: a gene selection resource for cancer genome projects. Nucleic Acids Res. 35, D721-D726 (2007).
36. Griffths-Jones, S., Saini, H.K., van Dongen, S. & Enright, A.J. miRBase: tools for microRNA genomics. Nucleic Avids Res. 36, D154-D158 (2008).
37. Dutt, A. et al. Drug-sensitive FGFR2 mutations in endometrial carcinoma. Proc. Natl. Acad. Sci. USA 105, 8713-8717 (2008).
38. Gordon, D., Abajian, C. & Green, P. Consed: a graphical tool for sequence fnishing. Genome Res. 8, 195-202 (1998).
39. Nickerson, D.A., Tobe, V.O. & Taylor, S.L. PolyPhred: automating the detection and genotyping of single nucleotide substitutions using fuorescence-based resequencing. Nucleic Acids Res. 25, 2745-2751 (1997).
40. Zhang, J. et al. SNPdetector: a software tool for sensitive and accurate SNP detection. PLOS Comput. Biol. 1, e53 (2005).
41. Major, J.E. Genomic mutation consequence calculator. Bioinformatics 23, 3091-3092 (2007).
42. Thomas, R.K. et al. High-throughput oncogene mutation profling in human cancer. Nat. Genet. 39, 347-351 (2007).
43. Reva, B., Antipin, Y. & Sander, C. Determinants of protein function revealed by combinatorial entropy optimization. Genome Biol. 8, R232 (2007).
44. Irizarry, R.A. et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4, 249-264 (2003).
45. Reich, M. et al. GenePattern 2.0. Nat. Genet. 38, 500-501 (2006).
46. Iafrate, A.J. et al. Detection of large-scale variation in the human genome. Nat. Genet. 36, 949-951 (2004).
47. Lin, M. et al. dChipSNP: signifcance curve and clustering of SNP-array-based loss-of-heterozygosity data. Bioinformatics 20, 1233-1240 (2004).
48. Ambrosini, G. et al. Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells. Mol. Cancer Ther. 7, 890-896 (2008).
49. Ambrosini, G. et al. Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1. Oncogene 26, 3473-3481 (2007).
50. Nishio, J. et al. Establishment of a novel human dedifferentiated liposarcoma cell line, FU-DDLS-1: conventional and molecular cytogenetic characterization. Int. J. Oncol. 22, 535-542 (2003).
51. Moffat, J. et al. A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell 124, 1283-1298 (2006).
52. Malo, N., Hanley, J.A., Cerquozzi, S., Pelletier, J. & Nadon, R. Statistical practice in high-throughput screening data analysis. Nat. Biotechnol. 24, 167-175 (2006).
53. Smyth, G.K. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat. Appl. Genet. Mol. Biol. 3, 3 (2004).
54. Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Statist. Soc. B 57, 289-300 (1995).